Advanced Research in Organs-on-a-Chip and Cancer
Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 1649
Interests: surface functionalization; engineering cell–material interface; biosensors and lab-on-a-chip; microfluidics; 3D bi-oprinting and 3D cell culture; organ-on-a-chip engineering
Special Issues, Collections and Topics in MDPI journals
Interests: tissue engineering; regenerative medicine; biomaterials; biomimetics; biodegradable materials; 3D in vitro models; cancer modelling
Special Issues, Collections and Topics in MDPI journals
2. ICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães, Portugal
Interests: biophysics; microfluidics; organ-on-a-chip; cancer; 3D in vitro models; bioengineering; tissue engineering; nano-technology; biomechanics
The lack of controllable preclinical models able to faithfully recapitulate the human cancer microenvironment impedes the development of novel therapies and limits our understanding of tumor etiology. Combining compartmentalized microfabricated platforms with advanced tissue engineering methods offers great potential for building biomimetic microfluidic models of human tissues and organs. These so-called ´organs-on-a-chip´ models have a unique capacity to, in vitro, recreate the biological complexity, mechanochemical cues, and fluid dynamics of native habitats of human cells and tissues, permitting the recapitulation of in vivo phenomena not achievable with traditional preclinical methods. Further, the inclusion of more complex 3D cellular structures, such as tumor organoids, and (bio)chemical signaling can recreate the interaction between cancer and its surrounding microenvironment in a more physiologically relevant manner, and, therefore, provide important clues to tumor etiology and progression.
Organ-on-a-chip technology has already provided key insights into organ and tissue pathophysiology and valuable information on drug efficacy, attracting significant attention from the industry and clinics as a result. In this regard, the use of organ-on-a-chip technology in oncology is a very promising method for the attainment of a better understanding of the mechanistic determinants of tumorigenesis, drug mechanisms of action or for evaluating the efficacy of therapies before testing them on patients. Currently, important efforts have been focused on adapting organ-on-a-chip platforms to the needs of targeted end-users, particularly clinicians. Despite the undeniable ability to reproduce the in vivo physiology and predict the response of therapeutics, this technology is still too complex and, in general, does not fulfill the strict requirements and functionality required by the clinical sector. For this reason, novel cutting-edge technologies have been applied to boost the clinical translation of organ-on-a-chip in oncology. Particularly, the use of standardized designs, the incorporation of analytical biosensors to detect and monitor predictive biomarkers, the compatibility with advanced imaging and conventional analytical techniques, the application of artificial intelligence and machine learning algorithms for the processing of gathered data, the integration of human-based and personalized (bio)materials or the possibility to purchase already pre-established tissue models-on-a-chip are expected to boost the clinical acceptance of this technology, particularly when combined with an improvement on their automation and high-throughput properties.
Overall, organ-on-a-chip technology has countless possibilities in academic, industrial and clinical cancer research. We are confident in its ability to continue to offer exciting novel developments and discoveries in upcoming years. We invite all those working in this revolutionary field to contribute to this Special Issue with original research articles, reviews, commentaries and perspectives in all relevant areas of research.
Prof. Dr. Josep Samitier
Prof. Dr. Rui L. Reis
Dr. David Caballero
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- tumor in vitro modelling
- 3D cell culture
- drug screening and dis-covery
- clinical applications
- personalized medicine